Chemoendocrine Therapy Linked to Greater Cognitive Decline in Breast Cancer Patients, Regardless of Menopausal Status
A secondary analysis of the RxPONDER trial finds chemoendocrine therapy causes more lasting cognitive impairment than endocrine therapy alone in both pre- and postmenopausal women.